pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update
The latest update as of July 31, 2017 has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO update are as follows:
- Seven new drug products have initiated pCPA negotiations since the last update, for a total of 46 active negotiations
- Three negotiations have been completed since the last update, for a total of 163 joint negotiations.
- Three new drug products were added to the “No pCPA Negotiations” list, for a total of 53 products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level
In addition to the information above, MORSE Consulting is tracking the number of products reviewed by CADTH that have yet to initiate negotiations with the pCPA – which we refer to as “under pCPA Consideration”. The latest update since June 30th, 2017 is:
- Five new drug products have received recent CDEC or pERC recommendations, for a total of approximately 23 products under pCPA Consideration
Please see below for more details.
- Seven new drug products have initiated pCPA negotiations since the last update, for a total of 46 active negotiations
- Cinqair (reslizumab; TEVA Canada Innovation) – Asthma, eosinophilic
- Giotrif (afatinib; Boehringer Ingelheim Canada Inc.) – Advanced Non Small Cell Lung Cancer
- Humira (adalimumab; AbbVie Corporation) – Hidradenitis suppurativa
- Kevzara (sarilumab; Sanofi Genzyme ) – Rheumatoid Arthritis
- Methadose (methadone; Mallinckrodt Pharmaceuticals) – Opioid dependence
- Trulicity (dulaglutide; Eli Lilly Canada Inc.) – Diabetes mellitus, Type 2
- Zykadia (ceritinib, Novartis Pharmaceuticals Canada Inc.) – Non-small cell lung cancer
- Three negotiations have been completed since the last update, for a total of 163 joint negotiations.
- Basaglar (insulin glargine; Eli Lilly Canada Inc.) – Diabetes mellitus, Type 1 and 2
- Mifegymiso (mifepristone/misoprostol; Celopharma Inc.) – Medical termination of pregnancy
- Votrient (pazopanib; pazopanib hydrochloride; GlaxoSmithKline Inc.) – Genitourinary metastatic renal cell carcinoma [second letter of intent]
- Three new drug products were added to the “No pCPA Negotiations” list, for a total of 53 products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level
- Alecensaro (alectinib; Hoffman-la Roche Ltd.) – Non-small cell lung cancer (with CNS metastases)
- Cortiment (budesonide; Ferring Inc.) – Ulcerative Colitis
- Viacoram (perindopril arginine/amlodipine; Servier Canada Inc.) – Hypertension
- The manufacturers and pCPA jurisdictions have engaged in thorough discussions regarding criteria and conditions as recommended through the HTA review and both recognize that a Letter of Intent (LOI) could not be reached at the current time.
Based on information collected by MORSE Consulting:
- Five new drug products have received recent CDEC or pERC recommendations or notifications to implement since the last update, for a total of approximately 23 products under pCPA Consideration.
Please note; the date provided is the date of the Final Recommendation or Notification to Implement where applicable.
- Cerdelga (eliglustat; Sanofi Genzyme; July 26, 2017) – Gaucher Disease
- Dysport Therapeutic (abobotulinumtoxinA; IPSEN Biopharmaceuticals Canada, Inc; July 26, 2017) – Cervical dystonia
- Glatect (glatiramer acetate; Pendopharm; July 25, 2017) – Multiple Sclerosis, relapsing- remitting
- Ninlaro (ixazomib; Takeda Pharmaceutical Company Limited; July 17, 2017) – Multiple Myeloma
- Ocaliva (obeticholic acid; Intercept Pharma Canada Inc; July 25, 2017) – Primary Biliary Cholangitis
Deciphering this Signal
- Basaglar – Completed its negotiations with the pCPA marking the first insulin glargine biosimilar product through the pCPA process.
- No pCPA Negotiations – After several months of having no products added to this list, in July the pCPA added 3 drugs to this list with additional details for Viacoram on the rationale for why a Letter of Intent could not be reached.
To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.
